By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Daiichi Pharmaceutical Co., Ltd. 

Japanese Headquarters
14-10 Nihonbashi 3-chome, Chuo-ku
Tokyo    103-8234  Japan
Phone: 03-3273-7101 Fax: 03-3281-8427


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Guilford Pharmaceuticals Inc.  Exclusive marketing, sales, and distribution rights to DOPASCAN ® Injection for Japan, Korea, and Taiwan.

Essential Therapeutics, Inc.   A 3 year collaboration entered into November 1995. The focus is on compounds that would overcome the efflux pump mechanism of bacterial resistance, to be used in combination with antibiotics targeting pseudomonas.





Company News
AstraZeneca PLC (AZN) And Daiichi Pharmaceutical Co., Ltd. Sign $100M Nexium Deal 10/29/2010 7:43:44 AM
Daiichi Pharmaceutical Co., Ltd. Names Dr. Jay Feingold Vice President, Medical Affairs Bolsters Company's Expertise in Areas of Oncology and Hematology 2/11/2010 10:50:04 AM
Daiichi Pharmaceutical Co., Ltd. Profit Forecast Disappoints, Shares Dive 5/12/2009 7:40:26 AM
Eli Lilly and Company (LLY) Release: Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) 12/19/2008 10:45:30 AM
Ranbaxy Laboratories Says Daiichi Pharmaceutical Co., Ltd. Deal on Track, Shares Rise 7/16/2008 6:41:01 AM
Daiichi Sankyo, Inc. Grants Priority Review for Daiichi Pharmaceutical Co., Ltd., Daiichi Pharmaceutical Co., Ltd. Drug, Prasugrel Investigational Antiplatelet Agent 2/22/2008 6:31:58 AM
Daiichi Pharmaceutical Co., Ltd. Receives Import Approval For Ultrasound Contrast Medium Sonazoid 10/26/2006 6:31:53 PM
Daiichi Pharmaceutical Co., Ltd. Selects MediData Solutions For Cost-Effective, Multilingual Clinical Trials 10/24/2006 11:24:52 AM
Daiichi Pharmaceutical Korea To Become Wholly Owned Subsidiary Of Daiichi Pharmaceutical Co., Ltd. 10/10/2006 9:45:17 AM
YM BioSciences (YM.TO) Licenses Monoclonal Antibody, Nimotuzumab, To Daiichi Pharmaceutical (JPN) For Japan; CIMYM BioSciences Inc. To Receive Up-Front Payment Of $14.5 Million 7/31/2006 10:53:12 AM
12345
//-->